Efficacy and executive function of olanzapine and risperidone in the treatment of elderly patients with schizophrenia

Abstract

Abstract: AIM: To explore the difference on efficacy and executive function between olanzapine and risperidone in treatment of elderly patients with schizophrenia. METHODS: 84 elderly patients with schizophrenia were randomly divided into olanzapine group (43 cases) and risperidon group (41 cases) treated for 8 weeks. The efficacy was assessed with the positive and negative symptoms scale (PANSS) and the executive function was evaluated with Wisconsin Card Sorting Test (WCST) in baseline and after 8 weeks of treatment. RESULTS: After 8 weeks of treatment, the efficacy rate of olanzapine was 90.6% , in which 67.4% was improved markedly. The efficacy rate of risperidon was 92.6%, in which 68.3% were improved markedly. There were no differences between two groups (P>0.01). The score of negative symptom of olanzapine group was significantly lower than that of risperidon group(P<0.05). The score of categories control in risperidon group was significantly lower than that in olanzapine group, persistent errors and response error were higher than that in olanzapine group(P<0.01). CONCLUSION: Both olanzapine and risperidon can improve the symptom and executive function of elderly patients with schizophrenia. Olanzapine is better than risperidon in improving negative symptom and executive function.

Key words: Olanzapine, Risperidon, Elderly patient, Schizophrenia, PANSS, Executive function

CLC Number:

R749

HANG Rong-hua, CHENG Wan-liang, WANG Rui-quan, WU Ming-fei. Efficacy and executive function of olanzapine and risperidone in the treatment of elderly patients with schizophrenia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 812-815.

References

[1] 袁国锋, 俞玉礼. 奥氮平治疗老年精神分裂症患者的疗效观察及对心电图的影响[J]. 中国临床药理学与治疗学, 2011, 16(3):304-308.
[2] Furtner J, Prayer D, Sachs G. Functional MRI in schizophrenia. Diagnostics and therapy monitoring of cognitive deficits of schizophrenic patients by functional MRI[J]. Radiologe, 2010, 50(2):131-135.
[3] Woodward ND, Purdon SE, Meltzer HY, et a1. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and Risperidone in schizophrenia[J].Int J Nenropsychopharmacol, 2005, 8(3):457-472.
[4] 胡恒章. 喹硫平与利培酮治疗老年精神分裂症的对照研究[J]. 中国临床药理学与治疗学, 2010, 15(2):203-205.
[5] 蔡飒, 陈一岳. 抗精神病药物治疗的进展[J]. 广东药学, 2004, 14(1):1-7.
[6] 李昌英, 宋志强, 崔国新. 奥氮平和奋乃静治疗老年期精神障碍对照研究[J]. 中国老年学杂志, 2009, 29(29):1016-1017.
[7] 姚芳传, 王克威. 精神科查房手册(第一版)[M].南京:江苏科学技术出版社, 2003:348-350.
[8] 谭西英, 甘景梨, 高存友. 精神分裂症患者的认知功能损害[J]. 国际精神病学杂志, 2011, 38(1):33-36.
[9] Barch DM. Pharmacological strategies for enhancing cognition in schizophrenia[J]. Curr Top Behav Neurosci, 2010, 4(4): 43-96.
[10] Gurpegui M, Alvarez E, Bousono M, et al. Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms[J]. Eur Neuropsychopharmacol, 2007, 17 (11):725-734.
[11] 赵峰, 高树贵, 谢曙光, 等. 利培酮对精神分裂症患者执行功能的影响[J]. 海峡药学, 2011, 23(9):79-80.
[12] Bender S, Dittmann-balcar A, Schall U, et al.Influence of atypical neuroleptic on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs clozapine[J]. Int J Neurop sychopharmacol, 2006, 9(2): 135-145.
[13] Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol[J]. Arch Gen Psychiatry, 2000, 57(3): 249-258.
[14] 舒畅, 王高华, 王惠玲.精神分裂症症状与威斯康星卡片分类测验成绩的相关性[J].中国心理卫生杂志, 2004, 18(8):580-582.
[15] Stip E, Chouinard S, Boulay LJ. On the trail of a cognitive enhancer for the treatment of schizophrenia[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2005, 29(2):219-232.